

(2017) Oncogene, 36 (1), p. 146.
The low-density lipoprotein receptor-related protein (LRP1B), encoding an endocytic LDL-family receptor, is among the 10 most significantly deleted genes across 3312 human cancer specimens. However, currently the apparently crucial role of this lipoprotein receptor in carcinogenesis is not clear. Here we show that LRP1B inactivation (by chromosomal, epigenetic and microRNA (miR)-mediated mechanisms) results in changes to the tumor environment that confer cancer cells an increased growth and invasive capacity. LRP1B displays frequent DNA copy number loss and CpG island methylation, resulting in mRNA underexpression. By using CpG island reporters methylated in vitro, we found that DNA methylation disrupts a functional binding site for the histone-acetyltransferase p300 located at intron 1. We identified and validated an miR targeting LRP1B (miR-548a-5p), which is overexpressed in cancer cell lines as a result of 8q22 DNA gains. Restoration of LRP1B impaired in vitro and in vivo tumor growth, inhibited cell invasion and led to a reduction of matrix metalloproteinase 2 in the extracellular medium. We emphasized the role of an endocytic receptor acting as a tumor suppressor by modulating the extracellular environment composition in a way that constrains the invasive behavior of the cancer cells. © 2011 Macmillan Publishers Limited All rights reserved.
| EMTREE drug terms: | histone acetyltransferaselow density lipoprotein receptor related proteinmatrix metalloproteinasemicroRNA |
|---|---|
| EMTREE medical terms: | animal cellarticlebinding sitecancer cell culturecancer inhibitioncancer invasionchromosomecontrolled studyCpG islandDNA methylationembryoendosomeepigeneticsextracellular matrixgene dosagegene expressionhumanhuman cellin vitro studyintronnonhumanpriority journalthyroid cancertumor growthtumor microenvironmenttumor suppressor gene |
histone acetyltransferase, 9054-51-7
| Funding sponsor | Funding number | Acronym |
|---|---|---|
| Ministry of Science, Technology and Space | ||
| Ministerio de Ciencia e Innovación | MICINN | |
| SFRH/BD30041/2006,PTDC/SAU-OBD/101242/2008 | ||
| Instituto de Salud Carlos III | ||
| PS09/02050-FEDER,13/2007 |
We would like to acknowledge funding from grants from the Portuguese Foundation for Science and Technology (SFRH/BD30041/2006 and PTDC/SAU-OBD/101242/2008), the Portuguese Society of Endocrinology and Metabolism (Edward Limber Prize) and the Portuguese Ministry of Health (project 13/2007). José Cameselle-Teijeiro was supported by Grant PS09/02050-FEDER, from the Ministry of Science and Innovation (Instituto de Salud Carlos III), Spain. IPATIMUP is an associated laboratory of the Portuguese Ministry of Science, Technology and Higher Education and is partially supported by the Portuguese Foundation for Science and Technology.
Soares, P.; Department of Cancer Biology, Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Rua Dr Roberto Frias s/n, Portugal;
© Copyright 2017 Elsevier B.V., All rights reserved.